This inventor holds 1 USPTO granted patent. Top assignee: Cytolynx Therapeutics Hong Kong Limited. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: The Innovations of Chanjuan Liu
Introduction
Chanjuan Liu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work is characterized by a focus on humanized therapies that target specific proteins involved in various diseases.
Latest Patents
Chanjuan Liu holds a patent for a "Humanized Monoclonal Antibody Targeting BCMA and Having Human Monkey Cross-Reactivity." This innovative patent highlights his expertise in creating targeted therapies that can potentially improve treatment outcomes for patients.
Career Highlights
Liu is currently employed at Cytolynx Therapeutics Hong Kong Limited, where he continues to advance his research and development efforts. His career is marked by a commitment to enhancing therapeutic options through innovative scientific approaches.
Collaborations
Throughout his career, Chanjuan Liu has collaborated with notable colleagues, including Ning Li and Guoqing Cao. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.
Conclusion
Chanjuan Liu's contributions to the field of biotechnology, particularly through his patent and work at Cytolynx Therapeutics, underscore his role as an influential inventor. His dedication to innovation continues to pave the way for advancements in medical therapies.